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Blood pressure lability and glomerulosclerosis after normoten-
sive 5/6 renal mass reduction in the rat.
Background. Hypertension plays a major role in the pro-
gression of both experimental and clinical chronic renal dis-
ease. However, the pathogenesis of the more slowly developing
glomerulosclerosis that is seen even in the absence of overt hy-
pertension, both in renal mass reduction models and in humans
with chronic renal disease, remains controversial.
Methods. The relationship of such glomerulosclerosis to the
ambient blood pressure profiles was examined in the normoten-
sive ∼5/6 surgical excision rat remnant kidney model. Blood
pressure was radiotelemetrically monitored at 10-minute inter-
vals for 15 to 16 weeks (∼15,000 blood pressure readings) in
untreated rats (N = 13), or those treated with enalapril (N =
8), amlodipine (N = 9), or a combination of hydralazine, reser-
pine, and hydrochlorothiazide (N = 10).
Results. Even in these normotensive rats (systolic blood pres-
sure <140 mm Hg), % glomerulosclerosis was significantly cor-
related with the overall average systolic blood pressure (r =
0.62, P < 0.0001; N = 40). However, much stronger correlations
were observed between glomerulosclerosis and the % systolic
blood pressure readings >150 mm Hg (r = 0.77, P < 0.0001) and
the standard deviation of the average systolic blood pressure (r
= 0.87, P < 0.0001).
Conclusion. These data indicate that pressure dependent in-
jury mechanisms continue to contribute to glomerular injury
even within the “normotensive” blood pressure range in rats
with reduced renal mass. This most likely represents the con-
sequence of the impairment of protective renal autoregulation
and enhanced glomerular transmission of the blood pressure
fluctuations into the hypertensive range characteristic of the
conscious state in both experimental animals and in humans.
Such pathophysiology supports the need for more aggressive
and around-the-clock blood pressure control in chronic renal
disease.
Models of renal mass reduction (RMR) have been
extensively used to investigate the pathogenetic mech-
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anisms responsible for the progressive nature of chronic
renal disease in humans [1–6]. Studies in the most fre-
quently employed hypertensive 5/6 renal ablation model,
which combines uninephrectomy with infarction of 2/3 of
the contralateral kidney, have demonstrated that hyper-
tension is a major determinant of the rate of development
of glomerulosclerosis of the initially normal remnant
glomeruli in this model [3, 5–10]. The validity of these
insights have been upheld by parallel clinical data, doc-
umenting the markedly deleterious effects of coexistent
hypertension on the progression of chronic human re-
nal disease [6, 11–14]. Indeed, aggressive antihyperten-
sive therapy is presently recommended to slow the rate
of progression in all patients with chronic renal disease
[11–14]. Consistent with such interpretations, when 5/6
RMR is achieved by surgical excision rather than by in-
farction, overt hypertension is usually not observed and
in contrast to the hypertensive infarction model, minimal
glomerular damage is observed in the remnant kidney of
such normotensive rats during the initial ∼6 weeks after
RMR surgery [15].
However, glomerulosclerosis does develop over time
in these normotensive rats [16, 17] in a manner analogous
to the often slower but continued progression of chronic
renal disease in “adequately” antihypertensive treated or
“normotensive” patients with chronic renal disease. The
pathogenesis of this slowly developing glomerulosclero-
sis in normotensive animals with 5/6 RMR remains con-
troversial. The very development of glomerulosclerosis
in the absence of hypertension in RMR models such as
uninephrectomy, has been used to provide support for
the postulate that the essential underlying pathogenesis
of glomerular sclerosis in rats with RMR may depend
upon blood pressure–independent mechanisms, such as
those related to increased expression and/or activation
of growth factors involved in the glomerular hypertro-
phy response [4, 18–22]. However, such interpretations
depend upon the assumed adequacy of conventional
tail-cuff blood pressure measurements to exclude or
accurately define a role for pressure-dependent injury
mechanisms and such assumptions have been shown
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to be not valid [9, 10, 14, 23–26]. The present stud-
ies were therefore performed to examine the corre-
lation on such glomerulosclerosis with blood pressure
parameters and glomerular hypertrophy using the tech-
nique of continuous chronic radiotelemetric blood pres-
sure monitoring in the normotensive 5/6 surgical excision
model in the rat. The rats were additionally either left
untreated or received antihypertensive therapy to pro-
duce additional variations in blood pressure within the
normotensive range.
METHODS
Animals and animal care
Male Sprague-Dawley rats weighing (200 to 250 g)
were obtained from Harlan Sprague Dawley, Inc. (In-
dianapolis, IN, USA). They were cared for in accordance
with the Principles of the Guide for the Care and Use of
Laboratory Animals (Department of Health, Education
and Welfare). They were housed in a constant tempera-
ture room with a 12-hour light and 12-hour dark cycle,
and as described below, they had free access to tap water
with or without the added antihypertensive agents.
Experimental protocols
The rats were anesthetized (sodium pentobarbital,
∼45 mg/kg intraperitoneally) and underwent right
nephrectomy with surgical excision of 2/3 of the left kid-
ney and instrumented for radiotelemetric cardiovascu-
lar monitoring as previously described [15]. They were
allowed to recover and housed individually in polycar-
bonate cages placed on radioreceivers connected to a mi-
crocomputer running LabPro data acquisition software
(Data Sciences International, Minneapolis, MN, USA).
Average systolic, mean, diastolic blood pressures and
heart rate, sampled at 500 Hz for a 10-second inter-
val, were recorded every 10 minutes throughout the day
and night for 15 to 16 weeks. After the first week, the
rats either received no treatment (N = 13), or one of
three antihypertensive regimens in their drinking wa-
ter: the angiotensin-converting enzyme (ACE) inhibitor,
enalapril (25 to 50 mg/L as tolerated) (N = 8), the dihy-
dropyridine calcium channel blocker, amlodipine (50 mg/
L) (N = 9) or a triple therapy regimen consisting of
hydralazine (80 mg/L), reserpine (5 mg/L), and hy-
drochlorothiazide (25 mg/L of drinking H2O) (N = 10).
At the end of 15 to 16 weeks, the rats were anesthetized
with inactin and underwent clearance studies as described
previously [15, 27]. In brief, a carotid artery was cannu-
lated with polyethylene (PE)-50 tubing and connected to
a Windograf (model 40–8474) (Gould, Inc., Glen Burnie,
MD, USA) for continuous recording of mean systemic
blood pressure. A femoral vein was cannulated with PE-
50 tubing, and a priming dose of inulin in 150 mmol/L
NaCl was administered, followed by a continuous main-
tenance infusion of 150 mmol/L NaCl containing inulin
at 0.055 mL/min to maintain the plasma concentration of
inulin at ∼50 mg/dL and for replacement of surgical and
ongoing fluid losses. The left ureter was then cannulated
with polyethylene tubing for collection of urine samples.
A 1.0 mmol/L R series flow probe (Transonic Systems,
Inc., Ithaca, NY, USA) was placed around the left re-
nal artery for measurement of renal blood flow (RBF)
by a flowmeter (Transonic Systems, Inc.), as described
previously [15, 27]. At the conclusion of the surgery, a
150 mmol/L NaCl bolus equal to 1% of body weight was
administered. Two 20-minute clearances of inulin were
obtained. Blood samples were obtained at the midpoint
of each urine collection. At the conclusion of these stud-
ies, the rats were killed, and the kidneys were harvested
for morphometric and morphologic studies. A 24-hour
urine protein sample was collected from each rat 2 to 3
days before the final surgery.
Histologic analysis
The kidneys were perfusion-fixed at the ambient pres-
sure as previously described [8–10, 15, 23]. In brief, the
kidneys were perfused with 150 mmol/L NaCl at 38◦C
until the venous effluent cleared, followed by modified
Karnovsky’s fixative (2% weight/volume paraformalde-
hyde and 2.5% glutaraldehyde in 0.1 mol/L cacodylate
buffer, pH 7.4) for 10 minutes. Two transverse sections of
the kidney through the papilla were post-fixed in buffered
formalin and embedded in paraffin. Sections (∼3 lm)
were stained with hematoxylin and eosin and periodic
acid-Schiff (PAS). Glomerular volume was measured by
area perimeter analysis (Bioquant System IV software;
R&M Biometrics, Inc., Nashville, TN, USA). The cross-
sectional area (AG) of 75 consecutive glomerular profiles
contained in one kidney section for each animal was mea-
sured using a digitizing pad as described previously [15].
The mean glomerular volume (VG) was then calculated
from the respective mean AG as VG = b/j (A3/2G ), where
b = 1.38 is the size distribution coefficient and j = 1.1
is the shape coefficient for glomeruli idealized as spheres
[15]. For the morphologic studies, sections were evalu-
ated systematically in each kidney for glomerulosclerosis
in a blinded fashion by standard morphologic methods.
At least 100 glomeruli in each animal were evaluated,
and the severity of glomerulosclerosis was expressed as
the percentage of glomeruli exhibiting such injury [8–10,
15, 23].
Analyses, calculations, and statistics
Urinary protein was measured by the quantitative sul-
fosalicylic acid method with human serum albumin serv-
ing as standard [8–10, 15, 23]. Serum creatinine was
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Table 1. Baseline and final data for renal functional and structural parameters
Initial Three days Final (15–16 weeks)
Body Serum Serum Body Serum Kidney
weight creatinine Proteinuria creatinine weight creatinine GFR RBF weight VG
g mg/dL mg/24 hours mg/dL g mg/dL mL/min/kg mL/min/kg g/kg um−3 × 10−6
NT (N = 13) 234 ± 4 0.37 ± 0.03 3.7 ± 0.8 0.66 ± 0.05 576 ± 20 0.60 ± 0.04 2.5 ± 0.46 29.1 ± 3.1 6.4 ± 0.3 3.5 ± 0.3
E (N = 8) 236 ± 6 0.38 ± 0.04 3.6 ± 0.6 0.74 ± 0.08 579 ± 24 0.49 ± 0.02 2.5 ± 0.30 31.2 ± 2.7 6.8 ± 0.6 4.0 ± 0.2
TT (N = 10) 230 ± 5 0.37 ± 0.03 2.5 ± 0.6 0.68 ± 0.08 512 ± 24 0.61 ± 0.03 2.8 ± 0.31 29.6 ± 2.0 7.6 ± 0.4 3.8 ± 0.4
A (N = 9) 241 ± 3 0.41 ± 0.03 2.3 ± 0.3 0.74 ± 0.03 513 ± 19 0.54 ± 0.04 2.9 ± 0.19 28.3 ± 2.0 7.2 ± 0.7 3.3 ± 0.2
Abbreviations are: GFR, glomerular filtration rate; RBF, renal blood flow; NT, no treatment; E, enalapril; TT, triple therapy; A, amlodipine.
measured using a creatinine analyzer (Beckman Instru-
ments, Inc., Fullerton, CA, USA). Inulin in urine and
plasma filtrates was determined spectrophotometrically
by the diphenylamine method as described previously [8–
10, 15, 23, 27]. Glomerular filtration rate (GFR) was cal-
culated using standard formulae. Statistical analysis was
performed using analysis of variance (ANOVA) followed
by Student-Newman-Keuls test or by Kruskal-Wallis
nonparametric ANOVA followed by Dunn’s multiple
comparison test as appropriate [28]. Linear regression
analysis was used to analyze the correlation between
glomerulosclerosis and blood pressure parameters and
to calculate the slope and intercepts. Overall averages for
the individual blood pressure parameters (systolic, mean,
and diastolic) were derived by averaging all of the blood
pressure values obtained during the final 14 to 15 weeks
as quantitative indices of overall average pressure bur-
dens for each of the parameters. Average pulse pressure
was calculated as the difference between systolic and di-
astolic blood pressure averages for each animal. To exam-
ine the potential impact of excursions of blood pressure
fluctuations into the hypertensive range, glomeruloscle-
rosis was additionally correlated with the percent of sys-
tolic blood pressure readings that exceeded 150 mm Hg.
The cutoff value of 150 mm Hg was chosen somewhat
arbitrarily based on the fact that values above 150 mm
Hg are generally agreed to be in the clearly hyperten-
sive range and blood pressure fluctuations in normal rats
rarely exceed this value [9]. Glomerulosclerosis was also
correlated with the standard deviation of the average sys-
tolic blood pressure, another index of blood pressure la-
bility and the amplitude of blood pressure fluctuations.
Analysis of covariance was used for comparison of these
parameters between groups. A P value of < 0.05 was con-
sidered statistically significant. All results are expressed
as mean ± SE.
RESULTS
Table 1 shows that the initial body weight, serum cre-
atinine, and 24-hour urine protein excretion were not
different between the four groups. Similarly, the serum
creatinine at 3 days was not different between the groups,
indicating comparable renal mass reduction in all groups.
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Fig. 1. Weekly averages of the course of radiotelemetrically measured
systolic blood pressure (BP) in rats with 5/6 renal mass reduction
(RMR) by surgical excision. They received no treatment (NT) or one of
the following three antihypertensive regimens in drinking water after
the first week: enalapril (E), 25 to 50 mg/L; a triple therapy regimen
(TT) of hydralazine, 80 mg; reserpine, 5 mg; and hydrochlorothiazide,
25 mg/L; or amlodipine (A), 50 mg/L. See text for details.
The weekly averages of systolic blood pressure in the un-
treated rats or the rats treated with one of the three anti-
hypertensive regimens are shown in Figure 1. All four
groups had similar systolic blood pressure in the nor-
motensive range during the first week, as is characteristic
of the surgical excision model. The institution of the an-
tihypertensive regimens initially reduced blood pressure
in all three groups with enalapril being the most effec-
tive. However, the antihypertensive effects of all three
regimens tended to wane over the ensuing weeks. This
loss of antihypertensive efficacy was most pronounced
for the amlodipine group and less so for the enalapril and
triple therapy groups. During the final 14 to 15 weeks af-
ter the initiation of antihypertensive therapy, the average
systolic blood pressure for the enalapril group was signif-
icantly lower than the untreated or amlodipine-treated
rats but was not statistically different than the triple ther-
apy group (Table 2). When the average systolic blood
pressure for the final 14 to 15 weeks of each of the groups
is compared to their respective first week pressures by
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Table 2. Blood pressure parameters (final 14–15 weeks)
Parameters NT E TT A
Systolic 128.9 ± 2.3 117.0 ± 2.3 121.8 ± 2.5 126.8 ± 1.3
Mean 108.1 ± 1.8 97.2 ± 1.6a 101.9 ± 2.1a 105.2 ± 1.4
Diastolic 91.4 ± 1.5 81.3 ± 1.2b 87.3 ± 1.8 88.5 ± 1.6
Pulse pressure 37.6 ± 1.5 35.7 ± 1.6 34.6 ± 1.5 38.3 ± 1.2
Heart rate 370 ± 4.7 369 ± 4.4 361 ± 3.9 352 ± 5.2a
SD, Systolic 10.9 ± 0.4 11.5 ± 1.1 10.4 ± 0.8 11.4 ± 1.5
SD, Diastolic 8.6 ± 0.3 9.3 ± 0.7 8.5 ± 0.6 8.6 ± 1.4
Abbreviations are: NT, no treatment; E, enalapril; TT, triple therapy; A,
amlodipine; SD, standard deviation.
aP < 0.05 maximum compared to NT; bP < 0.05 maximum compared to all
other groups.
paired t test, the untreated group showed a modest but
significant increase, while both the triple therapy and
enalapril groups demonstrated a significant reduction.
No significant difference was observed in the amlodipine
group due to the loss of antihypertensive effect over time.
Mean and diastolic pressures exhibited the same general
pattern (Table 2). However, no differences were noted
for pulse pressures between the groups, indicating a lack
of differential impact of these antihypertensive regimens
on systolic as compared to diastolic pressure. Of note,
the actual measured mean blood pressure in these rats
approximated diastolic pressures + ∼45% of the pulse
pressure rather than the ∼33% of the pulse pressure as
in humans probably due to the much faster heart rate
related differences in cardiac cycle in the rat. However,
there was little correlation between blood pressure pa-
rameters and heart rate (r = <0.15). Rather surprisingly,
the rats receiving hydralazine (triple therapy regimen)
did not exhibit an increased heart rate and the heart rate
was modestly but statistically significantly reduced in the
amlodipine group. As expected, a strong correlation was
observed between systolic and diastolic pressures (r =
0.82). But, pulse pressures were significantly correlated
with systolic (r = 0.69), but not diastolic pressures (r =
0.15).
Figure 2 illustrates the course of radiotelemetric sys-
tolic blood pressure recordings at 10-minute intervals
in a rat from each of the groups. Figure 2A graphically
displays the substantial spontaneous fluctuations of sys-
tolic blood pressure in an untreated rat. Such substantial
and comparable blood pressure lability was seen in all
groups as indicated by the mean standard deviations of
systolic and diastolic blood pressure during the final 14
to 15 weeks of the study. Figure 3 shows a 24-hour seg-
ment from the recording shown in Figure 2A from an
untreated rat and illustrates in more detail the general
pattern of blood pressure fluctuations with the accentua-
tion of blood pressure lability associated with nocturnal
feeding and activity.
At the conclusion of the studies at 15 to 16 weeks, there
were no differences in final body weight, serum crea-
tinine, RBF, GFR, kidney weight, and glomerular vol-
ume between the groups (Table 1). Figure 4 presents the
group data for % glomerulosclerosis and proteinuria. In
general, the majority of animals in all groups exhibited
modest glomerulosclerosis (<5%) and proteinuria. But
due to the more severe glomerulosclerosis in a minority
of rats in each group and the resulting scatter, the dif-
ferences between the groups for glomerulosclerosis and
proteinuria were not statistically significant. However, %
glomerulosclerosis and proteinuria were strongly corre-
lated in individual animals in all groups (r = 0.86, P <
0.0001). In general, almost all of the rats without signifi-
cant glomerulosclerosis (>1%) had proteinuria of 5 to 10
mg/day, a value comparable to that seen in sham-operated
controls [15]. The correlation between % glomeruloscle-
rosis and the ambient blood pressure profiles in individual
animals, the primary objective of the study, are presented
in Table 3 and Figure 5A to E. A greater correlation of
glomerulosclerosis was seen with the overall averaged
systolic and mean blood pressure during the final 14 to
15 weeks than with diastolic or pulse pressures and no
significant correlation with heart rate was observed.
The relationship of glomerulosclerosis to indices of
blood pressure lability is shown in Table 3 and Figure
5D and E. As Figure 5D shows, a very strong correlation
was observed between glomerulosclerosis and the stan-
dard deviation of average systolic blood pressure during
the final 14 to 15 weeks, an index of blood pressure labil-
ity and the amplitude of blood pressure fluctuations, with
a correlation coefficient of 0.87 (r2 = 0.76). Given the
strong correlation between systolic and diastolic blood
pressure, and between the standard deviations of systolic
and diastolic blood pressure (r = 0.93), an almost equally
strong correlation was observed between glomeruloscle-
rosis and standard deviation of diastolic blood pressure
(Table 3). Similarly, when the correlation of glomeru-
losclerosis with the percentage of systolic blood pressure
readings >150 mm Hg was examined (Fig. 5E), a very
strong relationship was also seen with a correlation co-
efficient of 0.77 and an r2 = 0.59. As one rat from the
triple therapy group clearly represented an outlier and
may have unduly impacted on the strength of the cor-
relations, the data were reanalyzed after the exclusion
of data from this rat. Such exclusion had minimal ef-
fects on the correlation of glomerulosclerosis with the
average systolic blood pressure (r = 0.61), average di-
astolic blood pressure (r = 0.47) or with the % of sys-
tolic blood pressure readings >150 mm Hg (r = 0.72),
but had more of an impact on the correlation of glomeru-
losclerosis with the standard deviations of systolic (r =
0.71) and diastolic blood pressure (r = 0.58). Neverthe-
less, all correlations remained highly statistically signifi-
cant with P < 0.001. As can also be noted from Figure 5A
to E, the effects of all antihypertensive regimens on
glomerulosclerosis in individual animals paralleled their
effects on the blood pressure parameters. The separate
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Fig. 2. Illustrations of the course of systolic blood pressure (BP) recorded every 10 minutes for 14 to 16 weeks after 5/6 renal mass reduction (RMR)
by surgical excision in a rat from each of four groups. (A) Untreated. (B) Enalapril. (C) Triple therapy. (D) Amlodipine. Note that although the
average systolic blood pressure values are well within the normotensive range, substantial systolic blood pressure fluctuations are seen in all rats
and often exceed a value of 150 mm Hg, particularly in the untreated rats.
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Fig. 3. Illustration of the pattern of systolic blood pressure (BP) fluc-
tuations in a decompressed 24-hour segment from the recordings shown
in Fig. 2A from an untreated rat.
correlation coefficients for the relationships between
glomerulosclerosis and systolic blood pressure parame-
ters within each of the four groups ranged between 0.55
to 0.92 with a maximum P value of <0.05, and signifi-
cant or consistent effects of antihypertensive regimens
on the slopes of the relationship between glomeruloscle-
rosis and the individual blood pressure parameters were
not observed (Fig. 5A to E). Figure 5F shows that the cor-
relation between % glomerulosclerosis and glomerular
volume was much weaker although still significant with a
correlation coefficient of 0.53 (r2 = 0.28; P < 0.001). How-
ever, if the one outlier rat was excluded, the correlation
coefficient decreased to 0.17 and became nonsignificant
(P > 0.05).
DISCUSSION
The results of the present study suggest that the mere
fact that glomerulosclerosis develops in normotensive
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Fig. 4. Proteinuria and % glomeruli with sclerosis at 15 to 16 weeks
after normotensive 5/6 renal mass reduction (RMR) in rats who were left
untreated (NT) or received enalapril (E), a triple therapy regimen(TT),
or amlodipine (A) after the first week following RMR surgery. See text
for details.
Table 3. Correlation of blood pressure parameters with
glomerulosclerosis
Parameters (N = 40) r2 P value
Systolic pressure 0.38 <0.0001
Mean pressure 0.34 <0.0001
Diastolic pressure 0.25 <0.001
Pulse pressure 0.19 <0.006
Heart rate 0.02 0.43
SD, Systolic 0.76 <0.0001
SD, Diastolic 0.68 <0.0001
SD, standard deviation.
rats may not be sufficient to exclude pressure-dependent
injury mechanisms or to infer a blood pressure–
independent pathogenesis of glomerulosclerosis. The pri-
mary basis for this apparent paradox stems from the
extensive body of experimental evidence, which has indi-
cated that it is not the elevation in systemic pressures per
se, but rather their enhanced transmission to glomerular
capillaries that is responsible for the greatly increased vul-
nerability to hypertensive injury of remnant glomeruli,
even with relatively moderate hypertension [3, 5–7, 9,
14, 29]. This exaggerated glomerular pressure transmis-
sion in the hypertensive 5/6 renal ablation model has
been shown to be a consequence of preglomerular va-
sodilation and an associated impairment of the normal
renal autoregulatory responses, which provide the pri-
mary protection against glomerular transmission of ele-
vated systemic pressures [29–34]. A logical implication of
the enhanced and freer glomerular transmission of sys-
temic pressures is that a much closer and steeper correla-
tion is expected to be observed between blood pressure
and glomerular injury in states of impaired as compared
to those with preserved autoregulation, as has indeed
also been demonstrated in the hypertensive 5/6 ablation
model [9, 10, 14, 15, 23].
The present observations extend these concepts to
“normotensive” rats with ∼5/6 RMR. Given that pre-
glomerular vasodilation and autoregulatory impairment
comparable to that in the hypertensive infarction model
are also observed in the normotensive surgical exci-
sion model [15, 34, 35], glomerular pressure transmission
would be expected to be enhanced, even within the nor-
mal blood pressure range in such rats. The very sig-
nificant correlation of glomerulosclerosis in these rats
after ∼16 weeks of RMR with their individual overall
averaged blood pressure parameters, particularly systolic
blood pressure profiles, suggests that despite the absence
of overt hypertension, pressure dependent injury mech-
anisms may nevertheless, contribute to the development
of glomerulosclerosis. However, the correlation between
average systolic blood pressure and glomerulosclerosis
was weaker than has been observed previously in the
hypertensive rats with 5/6 renal ablation despite a more
prolonged period of follow-up. This is probably not sur-
prising given the lower and rather narrow blood pres-
sure range observed in these normotensive rats and the
likelihood of the presence of a threshold relationship
between PGC elevations and glomerulosclerosis. Indeed,
micropuncture measurements in such normotensive rats
with 5/6 RMR have shown only relatively modest ambi-
ent increases in PGC (∼5 mm Hg) [8, 35]. It is possible
that these modest ambient PGC elevations, which would
be expected most of the time in these rats, have only a
limited pathogenetic potential. However, given the com-
promised autoregulatory responses to blood pressure in-
creases, episodic or sustained, the spontaneous, frequent,
and often large blood pressure fluctuations that are char-
acteristic of the conscious ambient blood pressure profile
both in experimental animals and in humans [9, 10, 14,
34–38] may have significant pathogenic consequences in
these RMR states. The much stronger relationship that
was observed in the present studies between glomeru-
losclerosis and indices of blood pressure lability such as
the standard deviations of systolic and diastolic blood
pressure during the ∼16 weeks of follow-up, and the per-
cent of systolic blood pressure readings >150 mm Hg
provide support for such interpretations of a threshold re-
lationship between increases in blood pressure (PGC) and
glomerulosclerosis. The stronger correlations of glomeru-
losclerosis with systolic rather than diastolic blood pres-
sure parameters also suggests, although it does not
establish, that glomerulosclerosis may be related to peak
(systolic) glomerular capillary pressures. Nevertheless,
these data are of interest, given the recent observations
indicating that, it is the systolic blood pressure that is the
trigger for the protective renal myogenic autoregulatory
responses [39]. Moreover, such interpretations are also
consistent with recent clinical observations showing bet-
ter correlation of target organ damage with systolic rather
than diastolic or mean blood pressure [40–42].
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Fig. 5. Correlations of % glomeruli with sclerosis at 14 to 15 weeks in individual rats with their own ambient radiotelemetrically measured blood
pressure (BP) profiles and glomerular volume. (A) Average systolic blood pressure. (B) Average mean blood pressure. (C) Average diastolic blood
pressure. (D) Standard deviation of overall average systolic blood pressure. (E) % Systolic blood pressure readings >150 mm Hg. (F) Glomerular
volume. Abbreviations are: NT, no treatment; E, enalapril; TT, triple therapy; A, amlodipine.
Taken together, these data suggest that due to the fun-
damental lability of blood pressure, transmission of sys-
temic pressures to glomerular capillaries, particularly in
states of impaired autoregulation, is also a dynamic and
time varying process [34, 37]. This has important impli-
cations for the investigation of the pressure-mediated
injury mechanisms. Conventional, periodic isolated
blood pressure measurements are inherently limited in
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providing an adequate and accurate assessment of ambi-
ent blood pressure profiles and/or defining the true rela-
tionship between blood pressure and renal damage. For
the same reason, PGC lability would be expected to paral-
lel blood pressure lability in the conscious state to a much
greater extent with impaired as compared to preserved
autoregulation. Therefore, isolated PGC measurements,
which have been used as a gold standard to establish
or dispute the contribution of pressure-dependent injury
mechanisms to the pathogenesis of glomerulosclerosis [3–
8, 18–22, 43], are also unlikely to provide an adequate in-
dex of glomerular capillary exposure to pressure burden
in such states of impaired autoregulation. This probably
accounts for the relatively poor correlations that have
been observed between glomerulosclerosis in individual
animals or in individual glomeruli in a given kidney and
conventionally measured blood pressure and/or PGC in
these models [18, 19, 22, 43]. And yet, exceeding close
correlations are demonstrated between glomerulosclero-
sis and blood pressure in individual hypertensive animals,
treated or untreated, when the ambient blood pressure
profile is adequately assessed in conscious animals with
RMR using blood pressure radiotelemetry [9, 10, 14, 15,
23].
With respect to the effects of the antihypertensive reg-
imens used in the present study, the effects on glomeru-
losclerosis in individual animals in general, paralleled
the effects of these agents on their ambient blood
pressure profiles. Interpretations regarding differences
or lack thereof, between the individual antihyperten-
sive regimens are limited by the generally modest de-
gree of glomerulosclerosis that was observed in most
animals in each of the groups, with few animals ex-
hibiting >10% glomerulosclerosis. Within the context
of these limitations, no consistently significant differ-
ences were observed between the individual regimens
with respect to the absolute severity of glomeruloscle-
rosis and/or its relationship to the individual blood pres-
sure glomerulosclerosis parameters examined (average
systolic, mean, and diastolic blood pressure, their stan-
dard deviations, and % systolic blood pressure read-
ings >150 mm Hg). Somewhat surprisingly, in contrast
to the prominent deleterious impact of the calcium
channel blockers on glomerulosclerosis observed in the
hypertensive 5/6 ablation model [44–46], an adverse ef-
fect of amlodipine was not seen in the present study.
This may stem from the fact that the dose of amlodip-
ine used in these normotensive rats was smaller than that
used in the hypertensive model (50 mg/L rather than 100
to 200 mg/L of drinking water) as well as the fact that
the pathogenetic threshold for blood pressure parame-
ters for the development of glomerulosclerosis over the
16-week time frame may not have been reached in the
majority of the normotensive amlodipine-treated rats.
Such an interpretation is consistent with our observa-
tions in the hypertensive 5/6 ablation model, which have
suggested that if blood pressure is reduced sufficiently
and well into the normotensive range, renoprotection
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may be achieved even with calcium channel blockers [14,
44–46].
A significant but much weaker correlation was also
observed between % glomerulosclerosis and glomeru-
lar volume in the present studies. This is in agreement
with the previously described frequent associations of
glomerular hypertrophy and glomerulosclerosis in both
RMR and diabetic states [18–22, 43]. Such associations
are often cited in support of a primary role for glomerular
hypertrophy per se in the pathogenesis of glomeruloscle-
rosis through maladaptive increases in expression and/or
activity of growth factors [18–22, 43]. However, associ-
ations between glomerular hypertrophy and glomeru-
losclerosis are usual but not invariable, and frequent
dissociations have also been noted, both experimen-
tally and clinically [46, 47]. For instance, the 5/6 surgi-
cal excision and the 5/6 infarction model exhibit com-
parable degrees of glomerular hypertrophy despite the
marked differences in the severity and course of glomeru-
losclerosis between the two models [15]. Similarly, in the
hypertensive 5/6 ablation model, administration of dihy-
dropyridine calcium channel blockers greatly enhances
the development of glomerulosclerosis without concur-
rent effects on glomerular hypertrophy either in stan-
dard or low protein diet–fed rats [44, 46]. Moreover, the
phase of most rapid growth, and presumably, the greatest
expression and/or activity of growth factor ceases long
before the development of glomerulosclerosis in nor-
motensive models of RMR and diabetes in both experi-
mental animals and in humans. Nevertheless, it is likely
that glomerular hypertrophy plays a permissive role in the
pathogenesis of glomerulosclerosis by magnifying the ad-
verse effects of elevated PGC as predicted by the Laplace
law (tension = pressure × radius) [8, 48, 49]. However,
in the absence of significant glomerular capillary hyper-
tension, the pathogenetic potential of glomerular hyper-
trophy per se may be more limited as in fact suggested
by the largely benign course of uninephrectomized renal
transplant donors in the absence of hypertension or other
complicating events. Conversely, with more severe
glomerular capillary hypertension, the degree of
glomerular hypertrophy may become relatively less im-
portant pathogenetically and this may account for the
observed dissociations.
Collectively, these observations not only provide addi-
tional insights into the pathogenesis of glomerulosclerosis
in RMR states, but may have important clinical implica-
tions with respect to the progression of chronic human
renal disease. It is of note that the limited observations
that are available in humans with a remnant kidney as a
consequence of tumor related partial resection of a soli-
tary functioning kidney, also suggest an increased risk of
proteinuria and progressive glomerulosclerosis even in
the absence of overt hypertension [50]. The present data
suggest that in terms of susceptibility to pressure medi-
ated glomerular injury, it may not be possible to clearly
define or separate hypertension from normotension in
states of reduced renal mass and/or impaired autoregu-
lation. The threshold for the adverse effects of increas-
ing blood pressure, particularly systolic blood pressure,
in such states may be significantly lower than previously
postulated and even transient elevations of systolic blood
pressure into the mildly hypertensive range may have
the potential for adverse effects on the development and
progression of glomerular injury. Such a pathophysiology
may in fact account for the relatively limited success thus
far in preventing the progression of renal disease even
with systolic blood pressure reductions to <140 mm Hg
with antihypertensive therapy [11–14]. This is in contrast
to the far greater success that has been achieved in pre-
venting stroke or malignant nephrosclerosis where the
threshold for target organ damage is much higher due to
preserved autoregulation, and even modest reductions in
blood pressure below such a threshold are successful in
preventing target organ damage [14, 25]. These interpre-
tations also provide a pathophysiologic basis for the cur-
rently recommended lower optimal blood pressure goals
in patients with diabetic and nondiabetic renal disease,
particularly in the presence of significant proteinuria [12,
13]. Additionally, these data also emphasize the need for
such blood pressure control to be maintained 24 hours a
day for the prevention of glomerular injury.
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